Nazarian G K, Bjarnason H, Dietz C A, Bernadas C A, Hunter D W
Department of Radiology, UMHC, University of Minnesota Hospital and Clinic, Minneapolis 55455-0392, USA.
Radiology. 1996 Jul;200(1):193-9. doi: 10.1148/radiology.200.1.8657909.
To assess effectiveness of metallic endovascular stents in treatment of venous stenoses and occlusions.
Stents were placed intravenously in 56 patients (59 stenoses or occlusions) over a 6-year period. Stent sites included the inferior vena cava (n = 10) and common iliac (n = 31), external iliac (n = 46), common femoral (n = 27), and superficial femoral veins (n = 4). Indications for stent placement included stenoses from pelvic malignancy and its treatment; trauma, surgery, or pregnancy; and idiopathic stenoses. Patients underwent anticoagulation therapy for 3-6 months after stent placement. Follow-up was performed with duplex ultrasound.
With use of life-table analysis, overall primary and secondary 1-year patency rates were 50% and 81%, respectively. Primary and secondary 4-year patency rates were and 50% and 75%, respectively. Five patients died of primary disease progression within 6 months after stent placement. Major complications occurred in 6.8% of cases. One-year secondary patency rates were statistically significantly lower (P = .05) for patients with malignant disease, although primary patency rates were comparable. Overall sustained decrease in symptoms (P < .0001) was observed 1 year later.
Endovascular stent placement is a nonsurgical alternative for reestablishment of venous flow and sustained relief of symptoms in patients with malignant or benign pelvic venous disease.
评估金属血管内支架治疗静脉狭窄和闭塞的有效性。
在6年期间,对56例患者(59处狭窄或闭塞)进行了静脉内支架置入术。支架置入部位包括下腔静脉(n = 10)、髂总静脉(n = 31)、髂外静脉(n = 46)、股总静脉(n = 27)和股浅静脉(n = 4)。支架置入的适应证包括盆腔恶性肿瘤及其治疗导致的狭窄;创伤、手术或妊娠;以及特发性狭窄。患者在支架置入后接受3 - 6个月的抗凝治疗。采用双功超声进行随访。
采用生命表分析,总体1年的初次通畅率和二次通畅率分别为50%和81%。4年的初次通畅率和二次通畅率分别为50%和75%。5例患者在支架置入后6个月内因原发疾病进展死亡。主要并发症发生率为6.8%。恶性疾病患者的1年二次通畅率在统计学上显著较低(P = .05),尽管初次通畅率相当。1年后观察到症状总体持续减轻(P < .0001)。
血管内支架置入术是一种非手术替代方法,可用于重建恶性或良性盆腔静脉疾病患者的静脉血流并持续缓解症状。